Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerus On Track To Complete Enrollment In Platelet Viral Inactivation Trials

This article was originally published in The Gray Sheet

Executive Summary

Enrollment of 600 patients in Cerus Corp.' s 12-center Phase III U.S. study of the company's blood platelet viral and bacterial inactivation compound S-303 will be completed by the first quarter of 2001, President and CEO Stephen Isaacs reported March 21 at the New York Society of Security Analysts health care conference in New York City.

You may also be interested in...



Cerus Corp.

Private placement of 1.2 mil. shares of common stock at $50 each raises $60 mil. to help fund R&D, clinical trials and general and administrative expenses. Cerus is collaborating with Baxter on a Phase III U.S. clinical trial of the Intercept Platelet System, as well as a Phase III U.S. trial of the Intercept Plasma System and Phase I trial of the Intercept Red Blood Cell System using Cerus-made compounds for pathogen inactivation (1"The Gray Sheet" March 27, 2000, p. 16). The financing increases Cerus' cash and investments to about $106 mil. "It is a pivotal time for Cerus as we prepare to file for regulatory approval for the Intercept Platelet System in Europe, and are working towards completion of Phase III clinical trials of the Intercept Platelet System and the Intercept Plasma System in the U.S.," the firm says

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.
UsernamePublicRestriction

Register

MT013148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel